ClinicalTrials.gov
ClinicalTrials.gov Menu

An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02376751
Expanded Access Status : No longer available
First Posted : March 3, 2015
Last Update Posted : June 8, 2016
Sponsor:
Information provided by (Responsible Party):
Alexion Pharmaceuticals

February 25, 2015
March 3, 2015
June 8, 2016
 
An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency

This is an open-label, multicenter expanded access protocol to allow patients with a confirmed diagnosis of Lysosomal Acid Lipase (LAL) Deficiency in the United States (US), access to sebelipase alfa (recombinant lysosomal acid lipase [rhLAL]) until commercial product is available.

Patients enrolled in the expanded access protocol will receive 1 mg/kg intravenous infusions of sebelipase alfa every other week.

Not Provided
Expanded Access
Drug: sebelipase alfa
Other Name: SBC-102, recombinant human lysosomal acid lipase, rhLAL
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
No longer available
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT02376751
Alexion Pharmaceuticals
Alexion Pharmaceuticals
Not Provided
Not Provided
Alexion Pharmaceuticals
November 2015